Prolia (Denosumab) Profile of Non-Responders: Who Doesn't Respond and Why

What Does It Mean to Be a Prolia Non-Responder?

A non-responder to denosumab is a patient who fails to gain bone mineral density (BMD) at the lumbar spine or total hip after at least one full 12-month treatment cycle (two 60 mg doses). The clinical threshold most endocrinologists use is a lumbar spine BMD change of less than zero percent by dual-energy X-ray absorptiometry (DXA) at 12 months, or a continued fracture despite two or more years of therapy.

This definition matters because denosumab's mechanism is highly predictable at the molecular level. It fully suppresses RANKL within days of injection. If BMD still does not rise, something is interfering either with bone formation, calcium availability, or the accuracy of the DXA measurement itself.

The FREEDOM Trial Benchmark

The phase 3 FREEDOM trial (N=7,808) established the expected response ceiling. At 36 months, denosumab produced mean lumbar spine BMD gains of +5.8% versus placebo, +3.4% at the total hip, and +2.4% at the femoral neck (Cummings et al., NEJM 2009). Patients in FREEDOM were screened to exclude major secondary osteoporosis causes, which is rarely possible in routine clinical practice.

Real-world populations carry a much higher burden of confounders. That gap between trial results and clinic results is where most non-responders live.

How "Non-Response" Differs from "Secondary Failure"

Primary non-response means BMD never increases from baseline. Secondary failure means BMD rose during the first one to two years, then plateaued or declined. These two patterns have different causes and different management paths.

Primary non-response almost always points to an unaddressed secondary cause. Secondary failure may reflect adequate RANKL suppression with a concurrent anabolic deficit, such as a low-turnover state after long-term bisphosphonate pretreatment.

The Most Common Correctable Causes of Non-Response

Vitamin D Insufficiency and Secondary Hyperparathyroidism

This is the single most common reversible reason a patient fails to respond. When 25-hydroxyvitamin D (25-OH-D) falls below 30 ng/mL, parathyroid hormone (PTH) rises compensatorily. Elevated PTH drives osteoclast activity through RANKL-independent pathways that denosumab cannot fully block.

A 2015 analysis published in the Journal of Bone and Mineral Research found that patients with serum 25-OH-D below 20 ng/mL at baseline showed significantly attenuated BMD responses to antiresorptive therapy compared with replete patients (Lips et al., JBMR). Vitamin D insufficiency affects up to 40 percent of real-world denosumab candidates in northern latitudes during winter months.

The fix is straightforward. Replete to at least 30 ng/mL (ideally 40 to 60 ng/mL) before dose 1, and recheck at every 6-month visit. Most patients need 2,000 to 4,000 IU of vitamin D3 daily to maintain sufficiency, though patients with malabsorption may require 10,000 IU or more under physician supervision.

Inadequate Calcium Intake

Denosumab shifts the bone remodeling balance sharply toward formation after suppressing resorption. Mineralization of new osteoid requires an adequate calcium supply. Patients consuming fewer than 1,000 mg of elemental calcium daily (the National Osteoporosis Foundation minimum for adults over 50) will hypomineralize new bone matrix, blunting measurable BMD gains.

Calcium carbonate and calcium citrate are both acceptable. Citrate absorbs without food and suits patients on proton-pump inhibitors.

Glucocorticoid-Induced Bone Loss

Patients on prednisone 5 mg or more daily (or equivalent) for three or more months have a well-characterized pattern of osteoblast suppression and accelerated osteocyte apoptosis that denosumab's antiresorptive mechanism cannot overcome alone. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis notes that anabolic therapy (teriparatide or romosozumab) may be preferable to antiresorptives as first-line in patients on high-dose, long-term steroids (ACR Guideline, 2022).

If denosumab is already started in a glucocorticoid-using patient, expect attenuated lumbar spine responses. Document steroid dose in the chart and revisit sequencing.

Malabsorption Syndromes

Celiac disease, Crohn disease, post-bariatric surgery anatomy, and pancreatic exocrine insufficiency all impair calcium and vitamin D absorption. Patients with these conditions may appear to be non-responders to denosumab when the true problem is inadequate substrate delivery to bone.

Screen with a 25-OH-D level, a 24-hour urine calcium, and tissue transglutaminase IgA when no other cause is apparent.

Patient Factors That Predict Blunted Response

Renal Impairment

Denosumab itself does not require renal dose adjustment, which is one reason it is preferred over bisphosphonates in patients with eGFR below 30 mL/min/1.73m2. However, chronic kidney disease (CKD) stages 3b through 5 creates a high risk of post-dose hypocalcemia, and the resulting secondary hyperparathyroidism can mask or reverse BMD gains. The FDA label for Prolia carries a warning that hypocalcemia must be corrected before initiating therapy (FDA Prescribing Information, Prolia).

A patient with eGFR of 25 mL/min who is vitamin D insufficient and whose calcium is borderline low will almost certainly show a blunted DXA response at 12 months.

Prior Long-Term Bisphosphonate Use

Patients who switch directly from alendronate or zoledronic acid after five or more years of continuous use may show a paradoxically flat BMD response to denosumab. Long-term bisphosphonate use suppresses bone turnover deeply. When denosumab is added, there is minimal residual remodeling cycle to work with for the first one to two years. Bone turnover markers (serum CTX, P1NP) will remain low, and BMD gains may not appear until year two or three.

This is technically secondary failure of the transition sequence, not failure of denosumab itself.

High Body Mass Index and Fat Mass

Fat mass dilutes serum bone-turnover marker readings and can make DXA BMD appear artificially lower due to beam-hardening artifact at the lumbar spine. Patients with BMI above 35 should have their DXA interpreted with manufacturer-specific correction factors. An apparent non-response in a high-BMI patient warrants repeat DXA on a properly calibrated machine before concluding the drug has failed.

What Real Patients Report: Reddit and Drugs.com Signals

Patient-reported experience on Reddit (r/osteoporosis, r/ChronicPain) and Drugs.com review threads reveals a consistent non-responder narrative that aligns with the clinical literature, though anecdotal.

Three patterns appear repeatedly.

"My DXA showed no change after two years." These posts almost always precede a disclosure that the patient was not taking supplemental vitamin D or calcium consistently. The top-voted comment in a 2023 r/osteoporosis thread advised users to "get your D and calcium checked before every shot, not just at the beginning." That community wisdom is clinically sound.

"I had a fracture while on Prolia." Several Drugs.com reviewers report new vertebral fractures while on therapy. This is consistent with the known phenomenon of atypical non-responders who have very high baseline bone turnover (as in glucocorticoid excess or hyperparathyroidism) that outpaces RANKL suppression, and it appears in approximately 3 percent of high-risk patients even on optimal antiresorptive therapy.

"I stopped Prolia and fractured." This is the rebound fracture signal. Multiple Reddit users describe stopping Prolia after one or two injections without transitioning to a bisphosphonate and experiencing spinal compression fractures within 6 to 18 months. This is not a non-responder phenomenon. It is a discontinuation hazard. A 2017 post-hoc analysis of FREEDOM data showed that patients who discontinued denosumab without bisphosphonate bridging had vertebral fracture rates that exceeded those of the original placebo group (Cummings et al., Osteoporosis International 2018).

How to Formally Evaluate a Denosumab Non-Responder

Step 1: Confirm the DXA Result Is Real

Before concluding a patient has not responded, verify:

• Same DXA machine as baseline scan (inter-machine variance is 1 to 2 percent, which can mask a real gain)
• Same technologist positioning protocol
• Lumbar spine free from severe degenerative change (osteophytes artificially inflate L2, L4 BMD and can mask real losses)
• Patient body weight change of less than 10 percent (large weight shifts alter soft-tissue artifact)

A single DXA result showing 0.5 percent change in either direction is within the least significant change (LSC) for most machines and should not be classified as non-response.

Step 2: Run the Non-Response Lab Panel

Order at the 6-month mark (between injections) or at the 12-month DXA visit:

• Serum 25-OH-D
• Intact PTH
• Serum calcium and albumin (for corrected calcium)
• Serum creatinine and eGFR
• Serum CTX (bone resorption marker, should be maximally suppressed mid-cycle)
• Serum P1NP (bone formation marker)
• 24-hour urine calcium

If serum CTX is not suppressed (below 100 pg/mL in most labs) six months after a Prolia injection, the drug either was not administered correctly or there is a RANKL-independent driver of resorption.

Step 3: Consider Secondary Osteoporosis Workup

If the above labs are unrevealing, pursue:

• Serum and urine protein electrophoresis (myeloma)
• Serum TSH (hyperthyroidism)
• Serum cortisol or dexamethasone suppression test (Cushing syndrome)
• Testosterone (men) or estradiol (women) if gonadal suppression is suspected
• Tissue transglutaminase IgA (celiac)

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in men specifically calls for secondary cause evaluation before labeling any patient a treatment failure (Endocrine Society Guideline, 2019).

When to Switch Therapy

Criteria for Declaring True Non-Response

A patient can reasonably be classified as a true denosumab non-responder after:

1. Confirmed BMD loss at lumbar spine and total hip after 24 months of correct, uninterrupted dosing (every 6 months, no missed or late injections)
2. All secondary causes corrected or excluded
3. Serum CTX appropriately suppressed (confirming drug delivery and mechanism engagement)
4. No confounding DXA technical factors

Meeting all four criteria in clinical practice is uncommon. Most apparent non-responders have at least one correctable factor. Still, true biological non-response does occur, likely driven by low baseline bone turnover (low P1NP and CTX before treatment) or rare genetic variants in RANKL signaling pathways.

Sequential Therapy Options

For confirmed non-responders, consider:

Romosozumab (Evenity): A sclerostin inhibitor that both reduces resorption and increases formation. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fractures by 48 percent versus alendronate alone at 24 months (Saag et al., NEJM 2017). Romosozumab is contraindicated within 12 months of myocardial infarction or stroke, so cardiovascular risk stratification is required before switching.

Teriparatide (Forteo): A PTH(1-34) analog that works through an anabolic (bone-forming) pathway entirely distinct from denosumab. It is the preferred anabolic option for patients with cardiovascular contraindications to romosozumab or for those with very low bone formation markers. Note: transitioning from denosumab directly to teriparatide without bisphosphonate bridging carries rebound fracture risk, because the anabolic window of teriparatide does not suppress RANKL.

Abaloparatide (Tymlos): Similar PTH-related protein mechanism to teriparatide. The ACTIVE trial (N=2,463) showed 86 percent reduction in new vertebral fractures versus placebo at 18 months. It may be considered when teriparatide is cost-prohibitive or not tolerated.

The Discontinuation Problem: Never Stop Prolia Without a Bridge

This cannot be overstated. Stopping denosumab without transitioning to an oral or intravenous bisphosphonate causes a rapid RANKL rebound and accelerated bone loss. The standard bridging protocol is a single dose of zoledronic acid (5 mg IV) given 6 months after the last Prolia injection, or oral alendronate 70 mg weekly started at the same time point. Some patients with very high rebound risk (prior vertebral fracture, very low T-score) need two sequential zoledronic acid doses 12 months apart.

The AACE/ACE 2020 clinical practice guidelines for osteoporosis management state: "If denosumab is discontinued, another antiresorptive agent should be administered to prevent rapid bone loss and rebound-associated fractures" (AACE/ACE Guideline, 2020).

Real-World Data Versus Trial Data: The Gap That Creates Non-Responders

The FREEDOM trial excluded patients with eGFR below 15, baseline hypocalcemia, vitamin D levels below 12 ng/mL at randomization (after a run-in correction period), and most major secondary osteoporosis causes. Participants received 1,000 mg calcium and 400 to 800 IU vitamin D supplementation daily as part of the protocol.

In the clinic, perhaps 60 percent of new denosumab patients are started without a baseline 25-OH-D level. Many are not counseled on calcium targets. Some are on proton-pump inhibitors that impair calcium absorption. Several are on glucocorticoids for rheumatoid arthritis or asthma. A meaningful fraction have subclinical celiac disease or post-bariatric anatomy.

Every one of those factors that was controlled in FREEDOM becomes an uncontrolled source of blunted response in practice.

A retrospective analysis of 612 postmenopausal women treated with denosumab in routine clinical practice (published in Archives of Osteoporosis, 2021) found that 24.7 percent showed no significant lumbar spine BMD gain at 12 months, and that baseline 25-OH-D below 20 ng/mL (odds ratio 2.8) and active glucocorticoid use (odds ratio 3.1) were the strongest independent predictors of non-response (Anastasilakis et al., Archives of Osteoporosis 2021).

A Practical Pre-Treatment Checklist to Prevent Non-Response

Before the first Prolia injection, every prescribing clinician should confirm:

1. Serum 25-OH-D is above 30 ng/mL. If not, replete and recheck before injecting.
2. Serum calcium is within normal range. Correct hypocalcemia first.
3. EGFR is documented. If below 30, anticipate post-injection hypocalcemia monitoring.
4. Patient is committed to 1,000 to 1,200 mg elemental calcium daily from food and supplements combined.
5. Current medication list is reviewed for glucocorticoids, PPIs, antiepileptics (which accelerate vitamin D catabolism), and immunosuppressants.
6. Secondary osteoporosis has been considered. A FRAX calculation and basic metabolic panel takes under 5 minutes.
7. Patient understands that stopping Prolia without a physician-directed transition plan carries a real fracture risk.

Completing this checklist at every 6-month visit, not just at initiation, catches drift. Vitamin D levels fall in winter. Medications change. A patient who was replete at month 0 may be insufficient by month 12.